Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro

Journal of Zhejiang University: Science B

Volumn 15, Issue 6, 2014, Pages 533-539

  Pang, Jing Yao ^a   Zhao, Kui Jun ^a   Wang, Jia Bo ^b   Ma, Zhi Jie ^a   Xiao, Xiao He ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b 302 MILITARY HOSPITAL   (China)

Author keywords

Antiviral activity; Epigallocatechin 3 gallate; Hepatitis B virus (HBV); HepG2 2.2.15; Lamivudine

Indexed keywords

EPIGALLOCATECHIN GALLATE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; CATECHIN; PLANT EXTRACT;

ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SUPERNATANT; TEA; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CAMELLIA SINENSIS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; PHYSIOLOGY;

ANTIVIRAL AGENTS; CAMELLIA SINENSIS; CATECHIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; IN VITRO TECHNIQUES; PLANT EXTRACTS; VIRUS REPLICATION;

EID: 84904054403     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1300307     Document Type: Article

References (21)

1. Abramovits, W., Gupta, A.K., 2010. Veregen (sinecatechins ointment) 15%. Skinmed, 8(1):46-49.
2. Ciesek, S., von Hahn, T., Colpitts, C.C., et al., 2011. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 54(6):1947-1955. [doi:10.1002/hep.24610]
3. Cui, X.Y., Inagaki, Y., Xu, H.L., et al., 2010. Anti-hepatitis B virus activities of cinobufacini and its active components bualin and cinobufagin in HepG2.2.15 cells. Biol. Pharm. Bull., 33(10):1728-1732. [doi:10.1248/bpb.33. 1728]
4. Fassina, G., Buffa, A., Benelli, R., et al., 2002. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS, 16(6):939-941. [doi:10.1097/00002030-200204120-00020] (Pubitemid 34409024)
5. Feld, J., Locarnini, S., 2002. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J. Clin. Virol., 25(3):267-283. [doi:10.1016/S1386-6532(02)00107-5] (Pubitemid 35287565)
6. Harada, S., Haneda, E., Maekawa, T., et al., 1999. Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol. Pharm. Bull., 22(10):1122-1126. [doi:10.1248/bpb.22.1122] (Pubitemid 29507957)
7. Hastak, K., Gupta, S., Ahmad, N., et al., 2003. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene, 22(31):4851-4859. [doi:10.1038/sj.onc.1206708] (Pubitemid 36981273)
8. + T cells by binding to CD11b. J. Allergy Clin. Immunol., 113(6):1211-1217. [doi:10.1016/j.jaci.2004. 02.044]
9. Kawai, K., Tsuno, N.H., Kitayama, J., et al., 2005. Epigallocatechin gallate induces apoptosis of monocytes. J. Allergy Clin. Immunol., 115(1):186-191. [doi:10.1016/j.jaci.2004.10.005] (Pubitemid 40075441)
10. Khan, N., Afaq, F., Saleem, M., et al., 2006. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res., 66(5):2500-2555. [doi:10.1158/0008-5472.CAN-05-3636]
11. Nakane, H., Ono, K., 1989. Differential inhibition of HIV-reverse transcriptase and various DNA and RNA polymerases by some catechin derivatives. Nucl. Acids Symp. Ser., (21):115-116.
12. Pang, R., Tao, J.Y., Zhang, S.L., et al., 2010. In vitro antiviral activity of lutein against hepatitis B virus. Phytother. Res., 24(11):1627-1630. [doi:10.1002/ptr.3155]
13. Park, N.H., Song, I.H., Chung, Y.H., 2006. Chronic hepatitis B in hepatocarcinogenesis. J. Postgrad. Med. J., 82(970): 507-515. [doi:10.1136/pgmj.2006.047431] (Pubitemid 44258625)
14. Perrillo, R.P., 2005. Current treatment of chronic hepatitis B: benefits and limitations. Semin. Liver Dis., 25(S1):20-28. [doi:10.1055/s-2005-915647] (Pubitemid 41254590)
15. Singh, R., Ahmed, S., Islam, N., et al., 2002. Epigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum., 46(8):2079-2086. [doi:10.1002/art.10443]
16. Steinmann, J., Buer, J., Pietschmann, T., et al., 2013. Antiinfective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Brit. J. Pharmacol., 168(5): 1059-1073. [doi:10.1111/bph.12009]
17. Stickel, F., Schuppan, D., 2007. Herbal medicine in the treatment of liver diseases. Dig. Liver Dis., 39(4):293-304. [doi:10.1016/j.dld.2006.11.004] (Pubitemid 46432239)
18. Xu, J., Wang, J., Deng, F., et al., 2008. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antivir. Res., 78(3):242-249. [doi:10.1016/j.antiviral.2007.11.011]
19. Yamaguchi, K., Honda, M., Ikigai, H., et al., 2002. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antivir. Res., 53(1):19-34. [doi:10.1016/S0166-3542(01)00189-9] (Pubitemid 33001552)
20. Zhang, L., Wang, G., Hou, W., et al., 2010. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology, 51(2):690-698. [doi:10.1002/hep.23384]
21. Zhen, M.C., Wang, Q., Huang, X.H., et al., 2007. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J. Nutr. Biochem., 18(12):795-805. [doi:10.1016/j.jnutbio.2006.12.016] (Pubitemid 350138426)